Advanced search
Publication Cover
Expert Opinion on Therapeutic Targets Volume 26, 2022 - Issue 6
Submit an article Journal homepage
296
Views
3
CrossRef citations to date
0
Altmetric
Review

Heterogeneity of triple-negative breast cancer: understanding the Daedalian labyrinth and how it could reveal new drug targets

Alberto Zambellia Medical Oncology and Hematology Unit, IRCCS - Humanitas Research Hospital, Rozzano - Milan, Italy;b Department of Biomedical Sciences, Humanitas University, Pieve Emanuele-Milan, ItalyCorrespondence[email protected]
View further author information
,
Riccardo Sgarrac Department of Life Sciences, University of Trieste, Trieste, ItalyView further author information
,
Rita De Sanctisa Medical Oncology and Hematology Unit, IRCCS - Humanitas Research Hospital, Rozzano - Milan, Italy;b Department of Biomedical Sciences, Humanitas University, Pieve Emanuele-Milan, ItalyView further author information
,
Elisa Agostinettob Department of Biomedical Sciences, Humanitas University, Pieve Emanuele-Milan, Italy;d Academic Trials Promoting Team, Institut Jules Bordet and l’Université Libre de Bruxelles (U.L.B), Brussels, BelgiumORCID Iconhttps://orcid.org/0000-0003-0295-7511View further author information
ORCID Icon,
Armando Santoroa Medical Oncology and Hematology Unit, IRCCS - Humanitas Research Hospital, Rozzano - Milan, Italy;b Department of Biomedical Sciences, Humanitas University, Pieve Emanuele-Milan, ItalyView further author information
&
Guidalberto Manfiolettic Department of Life Sciences, University of Trieste, Trieste, ItalyView further author information
Pages 557-573 | Published online: 08 Jun 2022

Citations (3)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Ernestina Marianna De Francesco, Francesca Cirillo, Veronica Vella, Antonino Belfiore, Marcello Maggiolini & Rosamaria Lappano. (2022) Triple-negative breast cancer drug resistance, durable efficacy, and cure: how advanced biological insights and emerging drug modalities could transform progress. Expert Opinion on Therapeutic Targets 26:6, pages 513-535.
Read now

Articles from other publishers (2)

Gyöngyi Munkácsy, Libero Santarpia & Balázs Győrffy. (2023) Therapeutic Potential of Tumor Metabolic Reprogramming in Triple-Negative Breast Cancer. International Journal of Molecular Sciences 24:8, pages 6945.
Crossref
Elisa Agostinetto, Flavia Jacobs, Véronique Debien, Alex De Caluwé, Catalin-Florin Pop, Xavier Catteau, Philippe Aftimos, Evandro de Azambuja & Laurence Buisseret. (2022) Post-Neoadjuvant Treatment Strategies for Patients with Early Breast Cancer. Cancers 14:21, pages 5467.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.